<sup>64</sup>CuCl<sub>2</sub> PET/CT in Prostate Cancer Relapse

Piccardo, Arnoldo; Paparo, Francesco; Puntoni, Matteo; Righi, Sergio; Bottoni, Gianluca; Bacigalupo, Lorenzo; Zanardi, Silvia; DeCensi, Andrea; Ferrarazzo, Giulia; Gambaro, M.; Ruggieri, F; Campodonico, Fabio; Tomasello, Laura; Timossi, Luca; Sola, Simona; Lopci, Egesta; Cabria, Manlio

doi:10.2967/jnumed.117.195628

Cited by 61 publications

(58 citation statements)

References 28 publications

(47 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lymphonodal involvement matched in three out of five patients with the corresponding magnetic resonance imaging (MRI), and in two patients, faint uptakes in bone metastases occurred. In a larger prospective study, Piccardo et al investigated the diagnostic potential of 64 CuCl 2 PET/CT in biochemical relapses of 50 PCa patients. 64 CuCl 2 PET/CT (60 min pi) demonstrated significantly higher detection rates compared with 18 F‐choline PET/CT (20 min pi) and MRI, in particular a higher detection rate in local recurrences.…”

Section: Discussionmentioning

confidence: 99%

“…The effective dose of 64 Cu‐PSMA‐617 seems to be comparable with 64 CuCl 2 , which is in the same dimension as 68 Ga‐PSMA‐617. The effective doses of 0.0283 mSv/MBq for 64 CuCl 2 and 0.021 mSv/MBq for 68 Ga‐PSMA‐617 lead to total doses of 5.7 and 4.2 mSv, respectively, for a standard activity of 200 MBq. However, some organ doses vary considerably, especially the liver dose.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Dual‐time‐point ⁶⁴Cu‐PSMA‐617‐PET/CT in patients suffering from prostate cancer

Hoberück

Wunderlich

Michler

et al. 2019

Labelled Comp Radiopharmac

View full text Add to dashboard Cite

Regardless of its high positron energy, 68 Ga-labeled PSMA ligands have become standard of care in metabolic prostate cancer imaging. 64 Cu, a radionuclide with a much longer half-life (12.7 h), is available for PSMA labeling allowing imaging much later than 68 Ga. In this study, the diagnostic performance of 64 Cu-labeled PSMA was compared between early and late scans. Sixteen men (median age: 70 y) with prostate cancer in different stages underwent 64 Cu-PSMA-617-PET/CT 2 and 22 hours post tracer injection. Pathologic and physiologic uptakes were analyzed for both points of time. Pathologic tracer accumulations occurred in 12 patients. Five patients presented with pathologic uptake in 17 different lymph nodes, two patients showed pathologic bone uptake in nine lesions, and seven patients had pathologic PSMA uptake in eight prostatic lesions. Physiologic uptake of the renal parenchyma, urine bladder, and salivary glands decreased over time, while the physiologic uptake of liver and bowel increased. In the present study, 64 Cu-PSMA-617-PET demonstrated to be feasible for imaging prostate cancer for both the primary tumor site and metastases. Later imaging showed no additional, clinically relevant benefit compared with the early scans. At least the investigated time points we chose did not vindicate the additional expenditure.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Dual‐time‐point ⁶⁴Cu‐PSMA‐617‐PET/CT in patients suffering from prostate cancer

Hoberück

Wunderlich

Michler

et al. 2019

Labelled Comp Radiopharmac

View full text Add to dashboard Cite

show abstract

“…[ 64 Cu]copper [1] ( 64 Cu) PET is characterized by high spatial resolution (positron range, 0.7 mm in water), and the radioactive half-life of 64 Cu (t 1/2 = 12.7 h) allows for in vivo assessment of copper biodistribution, even in compartments with slow copper turnover [4]. To date, only few 64 Cu PET studies of biodistribution and radiation dosimetry after intravenous injection in humans have been published, but it remains unclear which organs are the most critical in terms of radiation exposure [5][6][7]. In addition, no such studies have been published with oral administration of 64 Cu, the natural entrance route of copper in humans.…”

Section: Introductionmentioning

confidence: 99%

Intravenous and oral copper kinetics, biodistribution and dosimetry in healthy humans studied by [64Cu]copper PET/CT

Kjærgaard

Sandahl

Frisch

et al. 2020

Preprint

View full text Add to dashboard Cite

Purpose: Copper is essential for enzymatic processes throughout the body. [64Cu]copper (64Cu) positron emission tomography (PET) has been investigated as a diagnostic tool for certain malignancies, but has not yet been used to study copper homeostasis in humans. In this study, we determined the hepatic removal kinetics, biodistribution and radiation dosimetry of 64Cu in healthy humans by both intravenous and oral administration. Methods: Six healthy participants underwent PET/CT studies with intravenous or oral administration of 64Cu. A 90 min dynamic PET/CT scan of the liver was followed by three whole-body PET/CT scans at 1.5, 6, and 20 h after tracer administration. PET data were used for estimation of hepatic kinetics, biodistribution, effective doses, and absorbed doses for critical organs. Results: After intravenous administration, 64Cu uptake was highest in the liver, intestinal walls and pancreas; the gender-averaged effective dose was 62 ± 5 μSv/MBq (mean ± SD). After oral administration, 64Cu was almost exclusively taken up by the liver while leaving a significant amount of radiotracer in the gastrointestinal lumen, resulting in an effective dose of 113 ± 1 μSv/MBq. Excretion of 64Cu in urine and faeces after intravenous administration was negligible. Hepatic removal kinetics showed that the clearance of 64Cu from blood was 0.10 ± 0.02 mL blood/min/mL liver tissue, and the rate constant for excretion into bile or blood was 0.003 ± 0.002 min-1. Conclusion: 64Cu biodistribution and radiation dosimetry are influenced by the manner of tracer administration with high uptake by the liver, intestinal walls, and pancreas after intravenous administration, and after oral administration, 64Cu is rapidly absorbed from the gastrointestinal tract and deposited primarily in the liver. Administration of 50 MBq 64Cu yielded images of high quality for both administration forms with radiation doses approximately 3.1 and 5.7 mSv, respectively, allowing for sequential studies in humans.Trial Registration Number: EudraCT no. 2016-001975-59. Registration date: 19/09/2016.

show abstract

“…Molecular probes in nuclear medicine cover all hallmarks of cancer; therefore, alternative players have entered the scene , and compete directly on the same front. Some of these alternative players are agonists and antagonists of gastrin‐releasing peptide receptors (GRPRs), part of the bombesin family , and copper dichloride, transported at high‐affinity via the human copper transporter 1, which is well represented in human cancer, including prostate tumour cells . The common trait for both categories is their therapeutic potential, which still needs to be proven superior to the standard of care or to the experimental drugs in ongoing trials.…”

mentioning

confidence: 99%